Cingulate to Participate in Benzinga All Live Access Event
27 août 2024 16h30 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
27 août 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD
15 août 2024 07h45 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Willo Introduces Several New Product Enhancements to its Industry Leading Locking System, the Willo Wedge™
14 août 2024 11h00 HE
|
Willo Products Company
Willo Products Company, LLC announces the launch of the next generation of its revolutionary swinging door locking system platform.
Medsenic reçoit l'intention de délivrer un brevet européen clé de l'OEB, précieux pour le développement thérapeutique du trioxyde d'arsenic dans la sclérose en plaques récurrente-rémittente.
14 août 2024 01h00 HE
|
BioSenic
INFORMATION PRIVILEGIEE Le médicament de Medsenic, le trioxyde d'arsenic, peut maintenant être étudié pour le traitement de la sclérose en plaques par des cycles répétés d'administration par de...
Medsenic receives the intention to grant a key European patent from EPO, valuable for the therapeutic development of arsenic trioxide in relapsing-remitting multiple sclerosis
14 août 2024 01h00 HE
|
BioSenic
INSIDE INFORMATION Medsenic's experimental drug, arsenic trioxide, can now be investigated for the treatment of multiple sclerosis through repeated cycles of administration by multiple routes,...
Le brevet de Medsenic/BioSenic est accordé au Japon pour plus de protection de sa plate-forme thérapeutique
13 août 2024 12h00 HE
|
BioSenic
INFOMATION PRIVILEGIEE Le brevet sur la composition de la matière couvre l'utilisation thérapeutique des sels d'arsenic et des ions métalliques par diverses voies d'administration.Le portefeuille...
Medsenic/BioSenic patent granted in Japan for more protection of its therapeutic platform
13 août 2024 12h00 HE
|
BioSenic
PRIVILEGED INFORMATION Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administration.Enriched IP portfolio protects arsenic...
Mobiquity Technologies Partners with Context Networks to Transform Slot Machine Advertising in Casinos
13 août 2024 08h45 HE
|
Mobiquity Technologies, Inc.
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Mobiquity Technologies, Inc. (OTC: MOBQ), a leading provider of next-generation data intelligence and advertising technology solutions, proudly announces...
Neurotech Innovation Achieves Patent Approval and Featured Cover Story in Prominent Industry Journal
09 août 2024 09h00 HE
|
Longeviti Neuro Solutions
Longeviti, a neurotechnology company with a focus on innovative solutions for complex brain surgeries, announced its patent for its ClearFit Implant.